EUVIMEDEUVIMED entdecken
Beobachtungsstudie

An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada

Carolyn Owen, Sydney George, Sandra Thibault, Mariet Mathew Stephen, Mackenzie A Hamilton, Simar Gill, Winson Y Cheung

Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · e1229-e1240

DOI: 10.1016/j.clml.2026.08.001 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Carolyn Owen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Medical Oncology, University of Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Targeted fixed duration (FD) therapies have emerged as new treatment options that have been shown to be highly effective for patients with chronic lymphocytic leukemia (CLL). To date, there is limited Canadian data on the uptake and outcomes of CLL treatment following the approval of FD therapy. PATIENTS AND METHODS: This study was conducted to evaluate the clinical and demographic characteristics, treatment outcomes, and healthcare resource utilization (HCRU) of CLL patients treated with FD treatments in the 1L setting between 01 January 2010 and 31 December 2023 in Alberta, Canada. RESULTS: In total, 589 patients received therapy for CLL during this time period, and venetoclax plus obinutuzumab (VO) represented the most common therapy from 2021 to 2023. Additionally, patients receiving VO showed the highest survival rates at 12 months (95% confidence interval [CI]) at 97.6% (94.5, 100.0), followed by fludarabine, cyclophosphamide, and rituximab (FCR) at 96.6% (94.0, 99.3). CONCLUSION: These results highlight the shift in the treatment landscape for CLL with the potential for improved patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedMaleCanadaMiddle AgedAged, 80 and overTreatment OutcomeDuration of Therapy

Stichwörter der Autor:innen

Chronic lymphocytic leukemiaFixed durationOutcomesReal-world evidenceTreatments

Autor:innen und Institutionen

  • Section of Medical Oncology, University of Calgary, Alberta, Canada.
  • Scientific Affairs, AstraZeneca, Mississauga, Ontario, Canada.
  • Oncology Outcomes, Department of Oncology, Alberta, Canada.
  • Section of Medical Oncology, University of Calgary, Alberta, Canada; Oncology Outcomes, Department of Oncology, Alberta, Canada.
  • Section of Medical Oncology, University of Calgary, Alberta, Canada; Oncology Outcomes, Department of Oncology, Alberta, Canada. Electronic address: winson.cheung@oncoutcomes.com.

Zitieren

APA

Owen, C., George, S., Thibault, S., Stephen, M. M., Hamilton, M. A., Gill, S., & Cheung, W. Y. (2026). An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada. Clinical Lymphoma Myeloma and Leukemia, 26(10), e1229-e1240. https://doi.org/10.1016/j.clml.2026.08.001

Vancouver

Owen C, George S, Thibault S, Stephen MM, Hamilton MA, Gill S, et al. An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):e1229-e1240. doi:10.1016/j.clml.2026.08.001

BibTeX
@article{Owen2026,
  author = {Owen, Carolyn and George, Sydney and Thibault, Sandra and Stephen, Mariet Mathew and Hamilton, Mackenzie A and Gill, Simar and Cheung, Winson Y},
  title = {An Observational Study of Patients With Chronic Lymphocytic Leukemia Treated With Fixed Duration Therapy in a 1L Setting in Canada},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {10},
  pages = {e1229--e1240},
  doi = {10.1016/j.clml.2026.08.001}
}
Kostenlos starten →